Breast cancer risk with HRT, statins and colorectal cancer, and SBRT for lung metastases

Tuesday, November 3, 2020

News from MDedge Hematology-Oncology:

  1. New estimates for breast cancer risk with HRT: https://bit.ly/37VT0Pt
    BMJ study: https://bit.ly/2TKDIVt
    Lancet meta-analysis: https://bit.ly/3kUdbRl
  2. Single and multifraction SBRT found comparable for lung metastases: https://bit.ly/2HS36pR
  3. Statins may lower risk of colorectal cancer: https://bit.ly/3kLbR37

Email Blood & Cancer at podcasts@mdedge.com.

Follow us on Twitter @MDedgeHemOnc.

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.